Cargando…
Low Multiplicity of HIV-1 Infection and No Vaccine Enhancement in VAX003 Injection Drug Users
BACKGROUND: We performed human immunodeficiency virus type 1 (HIV-1) transmitted/founder (T/F) virus analysis of the VAX003 vaccine efficacy trial participants to characterize the transmission bottleneck and test for vaccine-associated reduction or enhancement of infection in this injection drug us...
Autores principales: | Sterrett, Sarah, Learn, Gerald H., Edlefsen, Paul T., Haynes, Barton F., Hahn, Beatrice H., Shaw, George M., Bar, Katharine J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4281816/ https://www.ncbi.nlm.nih.gov/pubmed/25734126 http://dx.doi.org/10.1093/ofid/ofu056 |
Ejemplares similares
-
Magnitude and Breadth of the Neutralizing Antibody Response in the RV144 and Vax003 HIV-1 Vaccine Efficacy Trials
por: Montefiori, David C., et al.
Publicado: (2012) -
Comparison of Antibody Responses Induced by RV144, VAX003, and VAX004 Vaccination Regimens
por: Karnasuta, Chitraporn, et al.
Publicado: (2017) -
Functional Antibody Response Against V1V2 and V3 of HIV gp120 in the VAX003 and VAX004 Vaccine Trials
por: Balasubramanian, Preetha, et al.
Publicado: (2018) -
VAX Cluster User's Guide
por: Bunn, Julian, et al.
Publicado: (1988) -
Three-year Efficacy and Safety of Takeda’s Dengue Vaccine Candidate (TAK-003)
por: Rivera, Luis, et al.
Publicado: (2021)